State Street’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-1,309,250
| Closed | -$78.3M | – | 3839 |
|
|
2019
Q4 | $78.3M | Sell |
1,309,250
-379,366
| -22% | -$14.2M | 0.01% | 1210 |
|
|
2019
Q3 | $47.4M | Sell |
1,688,616
-167,210
| -9% | -$5.71M | ﹤0.01% | 1482 |
|
|
2019
Q2 | $70.3M | Buy |
1,855,826
+470,384
| +34% | +$18.1M | 0.01% | 1263 |
|
|
2019
Q1 | $54.1M | Sell |
1,385,442
-246,529
| -15% | -$7.07M | ﹤0.01% | 1401 |
|
|
2018
Q4 | $34.8M | Buy |
1,631,971
+351,528
| +27% | +$9.07M | ﹤0.01% | 1591 |
|
|
2018
Q3 | $50.7M | Sell |
1,280,443
-29,061
| -2% | -$1.08M | ﹤0.01% | 1516 |
|
|
2018
Q2 | $50M | Buy |
1,309,504
+314,734
| +32% | +$11.7M | ﹤0.01% | 1490 |
|
|
2018
Q1 | $29.9M | Buy |
994,770
+420,809
| +73% | +$14.2M | ﹤0.01% | 1768 |
|
|
2017
Q4 | $17.9M | Buy |
573,961
+321,677
| +128% | +$8.83M | ﹤0.01% | 2118 |
|
|
2017
Q3 | $7.07M | Buy |
252,284
+31,008
| +14% | +$673K | ﹤0.01% | 2616 |
|
|
2017
Q2 | $4.23M | Buy |
221,276
+154,544
| +232% | +$2.47M | ﹤0.01% | 2818 |
|
|
2017
Q1 | $1.14M | Buy |
66,732
+3,752
| +6% | +$60.7K | ﹤0.01% | 3232 |
|
|
2016
Q4 | $1.15M | Buy |
62,980
+27,480
| +77% | +$475K | ﹤0.01% | 3250 |
|
|
2016
Q3 | $632K | Buy |
+35,500
| New | +$539K | ﹤0.01% | 3262 |
|
State Street's BOLD Position: Q1 2020 in Review
State Street sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 1,309,250 shares — an estimated $78.3M sold.
State Street first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $78.3M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- State Street reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- State Street sold 1,309,250 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $78.3M.
- State Street first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- State Street's Audentes Therapeutics, Inc position peaked at $78.3M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on State Street's 13F filing for Q1 2020, filed 11 May 2020.